Open AccessHPV Vaccination's Second Act: Promotion, Competition, and Compulsion
Author(s) -
Jason L. Schwartz
Publication year - 2010
Publication title -
american journal of public health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.284
H-Index - 264
eISSN - 1541-0048
pISSN - 0090-0036
DOI - 10.2105/ajph.2010.193060
Subject(s) - gardasil , vaccination , genital warts , opposition (politics) , public health , medicine , licensure , hpv vaccines , political science , human papillomavirus , attendance , vaccination policy , environmental health , family medicine , immunology , hpv infection , law , cervical cancer , politics , cancer , nursing , syphilis , human immunodeficiency virus (hiv)
Developments regarding human papillomavirus (HPV) vaccines will transform HPV vaccination in the United States while simultaneously raising several new policy and ethical concerns. Policymakers, vaccine manufacturers, and the public health community must now respond to the presence of competing vaccines that are similar but distinct, particularly with respect to genital wart prevention and the benefits of vaccinating males. This work arises in the shadow of the contentious introduction of the HPV vaccine Gardasil (Merck & Co, Inc, Whitehouse Station, NJ) in 2006, particularly the opposition to efforts in many states to require the vaccine for school attendance. I review the current status of HPV vaccine policy in the United States and examine issues of public health ethics and policy central to ongoing and future HPV vaccination programs.